OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Raza on Talquetamab Plus Teclistamab in R/R Myeloma and Extramedullary Disease

August 15th 2025

Shahzad Raza, MD, discusses talquetamab in plus teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Dr Pemmaraju on Responses With Pivekimab Sunirine in Frontline and R/R CD123+ BPDCN

August 15th 2025

Naveen Pemmaraju, MD, discusses phase 2 data with pivekimab sunirine in frontline or relapsed/refractory blastic plasmacytoid dendritic cell neoplasms.

Dr Scarfò on Early Safety Data With BGB-16673 in R/R CLL/SLL

August 15th 2025

Lydia Scarfò, MD, discusses early safety findings with the BTK degrader BGB-16673 in R/R CLL/SLL

Dr Schetelig on Challenges Assessing Haploidentical vs Mismatched Transplantation in AML/ALL/MDS

August 15th 2025

Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS

Dr Visentin on the Effects of Sequencing on Treatment Cost in CLL

August 14th 2025

Andrea Visentin, MD, discusses data from an Italian cost analysis of treatment sequencing in CLL.

Dr Halmos on Treatment Sequencing in Relapsed/Refractory NSCLC

August 14th 2025

Balazs Halmos, MD, discusses treatment sequencing considerations in the second line and beyond in NSCLC.

Dr Eroglu on Safety Considerations for Encorafenib/Binimetinib/Nivolumab in BRAF V600+ Melanoma

August 13th 2025

Zeynep Eroglu, MD, discusses management strategies for safe and effective use of encorafenib, binimetinib,and nivolumab in BRAF V600–mutant melanoma.

Dr Somaiah on Mutation-Specific Therapy in Gastrointestinal Stromal Tumors

August 13th 2025

Neeta Somaiah, MD, discusses the landscape of mutation-specific therapy for the treatment of patients with a gastrointestinal stromal tumor.

Dr Rathkopf on Niraparib Plus Abiraterone Acetate and Prednisone in HRR+ mCSPC

August 13th 2025

Dana E. Rathkopf, MD, discusses the clinical significance of findings from the phase 3 AMPLITUDE trial in HRR gene–mutated mCSPC.

Dr Jerkeman on Induction Chemoimmunotherapy Followed by High-dose Chemo and ASCT in Younger Patients With MCL

August 13th 2025

Mats Jerkeman, MD, discusses the use of induction chemoimmunotherapy followed by high-dose chemotherapy and ASCT in younger patients with MCL.

Dr Attard on Niraparib/Abiraterone Acetate Plus Prednisone in mCRPC With HRR Alterations

August 13th 2025

Gerhardt Attard, MD, PhD, FRCP, discusses niraparib plus abiraterone acetate and prednisone in mCSPC with HRR gene alterations.

Dr Bedke on the Safety Profile of Enfortumab Vedotin/Pembrolizumab in Previously Untreated Advanced Urothelial Carcinoma

August 13th 2025

Jens Bedke, MD, discusses the safety of enfortumab vedotin and pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma.

Dr Gopal on the FDA Approval of Tafasitamab in R/R Follicular Lymphoma

August 13th 2025

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

Dr Ansley on the Role of Elacestrant in ER+/HER2– Advanced Breast Cancer

August 12th 2025

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.

Dr Eroglu on the Study of Encorafenib Plus Binimetinib/Nivolumab in BRAF V600+ Melanoma With Brain Metastases

August 12th 2025

Zeynep Eroglu, MD, discusses the rationale for evaluating encorafenib plus binimetinib and nivolumab in BRAF V600-mutant melanoma with brain metastases.

Dr Randall on the Importance of Multidisciplinary Efforts in Sarcoma Management

August 12th 2025

R. Lor Randall, MD, FACS, discusses how suboptimal access to multidisciplinary, coordinated care remains a critical barrier to optimal outcomes in sarcoma.

Paulus on Leveraging Real-World Control Arms in Future HER2+ Breast Cancer Trials

August 12th 2025

Jessica Paulus, ScD, discusses the clinical implications of using real-world data to add an external control arm to a phase 2 study in HER2+ breast cancer.

Dr Pal on Future Research Directions With Adjuvant Immunotherapy in High-Risk Resected RCC

August 12th 2025

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

Dr Riess on Sequencing Considerations for KRAS and BRAF Inhibitors in NSCLC

August 12th 2025

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.

Dr Pal on the Predictive Utility of KIM-1 Expression in High-Risk Resected RCC

August 12th 2025

Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.